Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) ...

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients ...

Duchenne muscular dystrophy (DMD) in India faces challenges in diagnosis, treatment, and support, highlighting the urgent need for improvement.

Gene therapy could be the newest breakthrough for Duchenne muscular dystrophy. While it may not be a cure, it can give independence to boys diagnosed with DMD.

While genetic testing could not confirm Duchenne muscular dystrophy, a muscle biopsy at ... "It should slow the progression and hopefully actually help these boys regenerate some muscle," said ...

provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, Duvyzat will be available for ...

Through years of rigorous research, Duvyzat has consistently demonstrated a favourable risk-benefit profile and the potential to significantly delay disease progression across a broad range of ...

INDIANAPOLIS (WISH) — It’s a devastating diagnosis that changes a child’s life forever, Duchenne muscular dystrophy ... “It should slow the progression, and hopefully, actually help ...

Capricor Therapeutics is seeking FDA approval for CAP-1002, targeting heart function in Duchenne Muscular Dystrophy patients.

Elevidys is a prescription gene therapy developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). It targets the root cause of the disease by delivering a shortened but ...